je.st
news
Tag: merck
Merck 2Q profit tumbles on charges, lower revenue
2013-07-30 14:29:14| Biotech - Topix.net
In this Thursday, Feb. 28, 2013 photo, Merck scientist Meizhen Feng conducts research to discover new HIV drugs in West Point, Pa.
Tags: lower
charges
profit
revenue
Merck Announces Second-Quarter 2013 Financial Results
2013-07-30 13:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. 2013 Second-Quarter Non-GAAP EPS of $0.84, Excluding Certain Items; GAAP EPS of $0.30 Worldwide Sales were $11.0 Billion, a Decrease of 11 Percent Reflecting the Unfavorable Impact of Patent Expiries and a 3 Percent Negative Impact from Foreign Exchange Partially Offset by Global Performance of Human Health Products Growth in Key Franchises Including Vaccines, Diabetes and Immunology Continued Return of Cash to Shareholders, Including $5 Billion Accelerated Share Repurchase Announced in May Reaffirmed Full-Year Non-GAAP EPS Target of $3.45 to $3.55, Excluding Certain Items; Revised GAAP EPS Range to $1.84 to $2.05 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2013. $ in millions, except EPS amounts SecondQuarter2013 SecondQuarter2012 Language: English Contact: Merck & Co., Inc.Media Contacts:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461orInvestor Contacts:Carol Ferguson, 908-423-4465Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Merck Reaffirms Commitment to State AIDS Drug Assistance Programs (ADAPs) Through 2014
2013-07-30 00:32:01| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the ADAP Crisis Task Force (ACTF) today announced that the company will extend its commitment to support state AIDS Drug Assistance Programs (ADAPs), which have struggled to meet growing needs in recent years due to funding shortfalls. Through the new agreement, which extends through Dec. Language: English read more
Tags: state
programs
drug
assistance
Merck Applauds Colombia for First PAHO/WHO Verification of Elimination of River Blindness
2013-07-29 23:01:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Historic Milestone Reflects Successful Collaboration Among MECTIZAN Donation Program and Partners WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, applauds the government of Colombia whose work with the MECTIZAN Donation Program and The Carter Center-sponsored Onchocerciasis Elimination Program for the Americas led to todays Pan American Health Organization, the World Health Organizations Regional Office for the Americas (PAHO/WHO), verification of Colombia as the first country in the world to eliminate the transmission of river blindness (onchocerciasis), using MECTIZAN (iv Language: English Contact: MerckLainie Keller, 908-423-4187 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
river
colombia
verification
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 15:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MerckMedia:Pam Eisele, 908-423-5042Mary Elizabeth Blake, 908-423-5550orInvestors:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
Sites : [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] next »